The European Laboratory Research and Innovation Group (ELRIG) is preparing to host its flagship milestone event, ELRIG Drug Discovery 2026, marking the 20th anniversary of Europe’s premier drug discovery and life sciences conference. Scheduled to take place from October 14 to October 15, 2026, at the ExCeL London venue in the United Kingdom, the free-to-attend event is expected to convene thousands of researchers, industry leaders, technologists, and early-career professionals from across the globe.
As the life sciences sector navigates a complex landscape defined by rapid technological acceleration, shifting economic pressures, and evolving therapeutic modalities, the 20th-anniversary conference serves as both a retrospective on two decades of scientific collaboration and a forward-looking roadmap for the next era of pharmaceutical research. With 16 comprehensive scientific content tracks and over 150 expert speakers on the agenda, the two-day symposium will explore critical domains ranging from next-generation biophysics and CRISPR/Cas gene editing to microbiology, multiomics, and the integration of artificial intelligence in compound discovery and experimental design.
Main Facts and Event Overview
ELRIG Drug Discovery 2026 represents the culmination of 20 years of grassroots scientific community-building, education, and knowledge exchange. Founded with the mission to provide open-access, high-quality scientific conferences and symposia, ELRIG has grown to become a cornerstone of the European life sciences ecosystem. The decision to host the 20th-anniversary edition at ExCeL London underscores the event’s massive scale and its vital role as a neutral platform where academic researchers, big pharma executives, and emerging biotech innovators can meet without financial barriers, given the event’s enduring free-to-attend model.
The scientific program is structured around five core pillars: target identification and validation, assay development and screening, advances in chemistry and biophysics, disease models and translational science, and breakthrough technological paradigms such as artificial intelligence and machine learning. In addition to the technical tracks, the conference maintains a strong commitment to professional development, inclusivity, and mentorship, offering specialized networking spaces for early-career professionals and scientists navigating career transitions or redundancy within the biotech sector.
Chronology and Key Program Highlights
Day One: Wednesday, October 14, 2026
The conference gates open at 8:00 AM BST with registration, immediately followed by morning meet-and-greets designed to foster community support. These sessions provide a collaborative environment for early-career researchers and professionals facing career restructuring to share insights, build networks, and access peer-to-peer mentorship over morning refreshments.
At 9:00 AM, ELRIG Chair Del Trezise will deliver the official welcome address in Auditorium 1, reflecting on two decades of community resilience, scientific advancement, and growing inclusivity within the organization. This will immediately precede the opening plenary keynote at 9:25 AM delivered by Dr. Sam Barrell, CEO of LifeArc, a prominent medical research charity based in London. Dr. Barrell’s address, titled "Where Need Meets Momentum: The Next 20 Years," will set the intellectual tone for the conference, offering a strategic analysis of translational research bottlenecks, funding landscapes, and the future trajectory of drug development.
The morning schedule also features the presentation of two major industry accolades starting at 10:10 AM in Auditorium 1:
- The Outstanding Contribution Award, honoring an individual whose sustained efforts have significantly shaped ELRIG and the broader drug discovery community.
- The Innovation Prize, recognizing an organization or research group responsible for developing a transformative technology or methodological approach capable of redefining drug discovery and development pipelines.
Following the morning ceremonies, the first major poster session will occupy the Learning Zone from 12:55 PM to 2:00 PM, showcasing cutting-edge pre-clinical data from hundreds of academic and industrial researchers.
The afternoon oral sessions feature targeted presentations across specialized tracks:
- CRISPR Applications in Oncology (12:20 PM – 12:50 PM, Tech Theatre): Lovely Paul Solomon Devakumar, Senior Scientist at the Functional Genomics Centre in Cambridge, UK, will present novel insights into the application of CRISPR screening methodologies for identifying and validating therapeutic targets within complex cancer signaling networks.
- In-Cell NMR Breakthroughs (2:40 PM – 3:10 PM, Auditorium 4): Professor Lucia Banci, founder of the University of Florence’s Center of Magnetic Resonance in Italy, will demonstrate the utility of in-cell nuclear magnetic resonance (NMR). This technique permits the detection of individual proteins within living human cells at atomic resolution, enabling direct drug screening analyses inside native cellular environments.
- Digital Twins and Causal Cell Models (3:45 PM – 4:15 PM, Auditorium 2): Dr. Yann Abraham, Head of Drug Discovery at DeepLife in Paris, France, will introduce TwinCell. This large causal cell model integrates single-cell foundational modeling, interactome mapping, and in vitro perturbational data to optimize therapeutic target prioritization and drive drug repositioning strategies.
- The Future of AI and Experimental Design (4:30 PM – 5:00 PM, Auditorium 2): A high-profile panel discussion addressing the transformative impact of artificial intelligence on design of experiments (DoE) workflows, predictive toxicology, and automated synthesis laboratories.
Day Two: Thursday, October 15, 2026
The second day commences at 9:00 AM in Auditorium 1 with a series of prestigious award presentations celebrating excellence across various career stages and operational dimensions:
- The Early Career Professional Poster Award, recognizing exceptional visual and data-driven communication by junior scientists during day one sessions.
- The ELRIG Sustainability Award, acknowledging companies or individuals implementing pioneering operational or technological initiatives to minimize the environmental footprint of laboratory research and life sciences operations.
- The Kirsty Smitten Award, an early career research prize commemorating scientific excellence, leadership, and philanthropic contributions to pre-clinical drug discovery and technology development.
A secondary poster session will run from 1:10 PM to 2:30 PM, providing continued visibility for emerging research projects.
Key oral sessions scheduled for Thursday include:
- Two Decades of Discovery: Lessons from the Past (9:30 AM – 10:15 AM, Auditorium 1): A flagship anniversary keynote panel chaired by Saleha Patel of ELRIG and Constructive Bio. The panel features prominent industry leaders including Anne Phelan (GSK), Jason Mellad (OtoImmune), Mene Pangalos (AstraZeneca), and Raghib Ali (Our Future Health). Together, they will dissect the structural shifts, pipeline successes, and clinical failures that have defined the past 20 years of pharmaceutical research, offering strategic foresight for upcoming decades.
- Tissue Platforms in Endometriosis (11:55 AM – 12:25 PM, Auditorium 4): Léa Wenger, CEO and co-founder of Cyclana Bio in Cambridge, UK, will address the critical unmet medical need in endometriosis—a condition affecting an estimated 190 million reproductive-age women globally. Wenger will discuss her team’s work utilizing the extracellular matrix to build sophisticated tissue platforms aimed at accelerating early diagnosis and effective therapeutic development.
- AI-Driven Drug Repurposing (12:40 PM – 1:10 PM, Auditorium 3): Layla Hosseini-Gerami, co-founder and Chief Data Science Officer of Ignota Labs in Cambridge, UK, will explore the intersection of chemistry, biology, and machine learning. Her presentation will showcase how computational pipelines can systematically re-evaluate failed pharmaceutical compounds, identifying novel safety profiles or secondary indications to give abandoned molecules a second clinical chance.
- Microbiome-Derived Antimicrobial Peptides (2:30 PM – 3:00 PM, Tech Theatre): Dr. Linda Oyama, Senior Lecturer in Microbiomics, Antimicrobial Resistance, and One Health at Queen’s University Belfast, Northern Ireland, will discuss her research into culture-dependent, meta-omic, and computational techniques. Her work targets the discovery of novel antimicrobial peptides derived from complex microbiomes to combat escalating drug-resistant fungal and bacterial infections threatening human and animal health.
Supporting Data and Industry Context
The convening of ELRIG Drug Discovery 2026 arrives at a critical juncture for the global biopharmaceutical sector. According to recent industry analytics, global R&D spending by top pharmaceutical companies continues to scale upwards, driven by the mounting complexity of pipelines, the expiration of major blockbuster drug patents (the "patent cliff"), and the imperative to translate basic genetic discoveries into clinically viable therapies.
At the same time, the integration of artificial intelligence and machine learning into drug discovery has transitioned from an experimental novelty to an operational necessity. Industry surveys indicate that over 70% of major biopharma organizations have integrated AI-driven target discovery or compound screening platforms into their early-stage workflows, resulting in compressed discovery timelines and reduced attrition rates in pre-clinical phases. However, industry stakeholders frequently emphasize that computational models remain fundamentally dependent on high-quality, standardized biological data—underscoring the vital importance of foundational platforms such as CRISPR screening, in-cell NMR, and advanced tissue modeling models highlighted throughout the conference agenda.
Furthermore, the emphasis on sustainability—exemplified by the ELRIG Sustainability Award—reflects a broader cultural and operational shift within the life sciences sector. Academic laboratories and industrial facilities consume vast quantities of energy, single-use plastics, and water resources. The adoption of green chemistry principles, automated waste-reduction protocols, and energy-efficient high-throughput screening technologies is increasingly recognized not only as an ethical obligation but as an operational imperative mandated by institutional investors and international regulatory frameworks.
Broader Impact and Implications
The implications of ELRIG Drug Discovery 2026 extend far beyond the immediate exchange of academic papers and commercial technology demonstrations. By maintaining a zero-cost attendance model, ELRIG actively democratizes access to high-level scientific education, ensuring that independent researchers, students, and scientists from underfunded academic institutions or developing economic regions can engage directly with global industry leaders. This accessibility directly fosters collaborative networks that transcend traditional institutional and geographical boundaries.
From a therapeutic development perspective, the specialized tracks focusing on oncology target validation, antimicrobial resistance, and neglected or difficult-to-treat conditions like endometriosis address some of the most persistent clinical challenges of the 21st century. As antimicrobial resistance threatens to undermine modern medicine, and as chronic conditions place unprecedented strains on healthcare systems, the translation of microbiome research, causal cell models, and AI-assisted drug repurposing from the bench to the clinical pipeline holds profound socioeconomic value.
As the doors at ExCeL London open in three weeks, ELRIG Drug Discovery 2026 stands as a testament to the resilience, adaptability, and collaborative spirit of the global life sciences community. By honoring two decades of past achievements while aggressively interrogating the technological and methodological frontiers of tomorrow, the conference will undoubtedly shape the strategic trajectory of drug discovery for years to come.
